Centre Hospitalier De Bourg-En-Bresse
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Centre Hospitalier De Bourg-En-Bresse, clinical research in cardiovascular diseases focuses on acute ischemic stroke and high-risk transient ischemic attack. These studies are designed to assess whether new treatment approaches can better prevent recurrent stroke and improve protection after a recent cerebrovascular event.
- Evaluating whether a new therapy can lower the risk of another ischemic stroke after a recent event
- Studying treatment strategies for patients with acute stroke-related conditions
- Improving care for people at high risk of further neurological complications
This area reflects a strong interest in better prevention and treatment of serious cerebrovascular disease in the intensive care setting.
Bacterial Infections and Mycoses
Research in bacterial infections at this site centers on severe community-acquired bacterial pneumonia. The trials are exploring whether adding new supportive treatments to standard care can improve recovery, while also checking their safety and tolerability in patients with serious lung infection.
- Testing a potential new treatment for severe pneumonia
- Assessing whether patients recover faster when additional therapy is used with standard care
- Evaluating the safety and tolerability of infection-focused treatment approaches
This work highlights the site’s role in studying better ways to manage serious respiratory infections that can lead to critical illness.
Respiratory Tract Diseases
In the area of respiratory tract diseases, the Unité de soins intensifs is involved in research on de novo acute respiratory failure. The main goal is to improve treatment pathways and help patients come off high-flow nasal oxygen therapy more successfully.
- Studying a protocol to support safer and more effective weaning from oxygen therapy
- Looking at ways to increase the chance of being off high-flow oxygen by day 7
- Improving recovery for patients with acute breathing failure in intensive care
These trials focus on practical care improvements for patients with acute respiratory failure, aiming to strengthen outcomes in the intensive care environment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 61 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Bourg-En-Bresse
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-associated tracheobronchitis (AMIVAT) | Centre Hospitalier Regional Universitaire De Tours | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 6 | Unknown | 2017-03-22 | 2026-04-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.